Navigation Links
Spectros Corporation Sales and Licensing Revenue Up 32% in 2010
Date:2/10/2011

PORTOLA VALLEY, Calif., Feb. 10, 2011 /PRNewswire/ -- Spectros Corporation announces that sales and licensing revenue rose 32% (year-over-year) in 2010. This is the third year in a row for double-digit revenue growth for Spectros since the current T-Stat product line was launched in 2008. Spectros released certain 2010 financial results to shareholders today.

"This is a sign of the significant and growing reliance of physicians, patients, and hospitals on state-of-the-art tissue oximetry and spectroscopy devices and disposable sensors," notes CFO John Bagnatori.

"Due to the wide range of applications the T-Stat VLS Tissue Oximetry system may be applied to, it has been important to focus on the markets that perform strongest and will provide the greatest longevity," states Elizabeth van Thillo, director of Marketing. "We are excited at the rate of which sales and marketing efforts are ramping up and showing returns. Overall, we anticipate seeing a strong 2011 with the increasing adoption of tissue oximetry."

Spectros T-Stat® VLS Tissue Oximter and Continuum® Tissue Oximeters are the only broadband tissue oximeters on the market in the U.S. and Europe. T-Stat® and Continuum® compete in the marketplace with INVOS® oximeters marketed by Covidien. An expanded array of sensors, including Continuum® cerebral sensors are currently in testing, pending FDA approval and release anticipated over the next year.

About Spectros

Spectros markets and licenses advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's champion product, the T-Stat VLS Tissue Oximeter, is the first medical device FDA-approved as sensitive to ischemia, an insufficient supply of oxygen to tissue.  T-Stat is the only commercially available tissue oximeter that utilizes state-of-the-art multispectral visible light spectroscopy (VLS) technology.  The non-invasive T-Stat VLS system is used clinically to provide a continuous and real-time absolute value, utilizing 260 wavelengths, over the competing NIRS oximeter product lines that only use 2-4.

Spectros also develops molecular diagnostic tools for breast and prostate cancer, currently in phase I/II clinical trials supported by the National Cancer Institute.  Spectros is a venture-supported private concern and markets its products in the U.S. and internationally.

(Note:  Forward-looking statements are intended as a guide only, and do not constitute an offer for investment nor a guarantee of future events or returns.  Certain Spectros applications described above have not been reviewed and approved by the FDA, and are therefore labeled for investigational use only.  T-Stat and Continuum are trademarks of the Spectros Corporation. INVOS is a trademark of Somanetics and Covidien).

For further information, visit www.spectros.com.


'/>"/>
SOURCE Spectros
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Spectros White LED Patent Scope Affirmed In U.S. Patent Office Reexamination
2. Spectros Presents New Clinical Studies Using T-Stat VLS Tissue Oximeter at Anesthesiology 2010
3. ICAP Ocean Tomo Offers IP Portfolio of Near-Infrared Spectroscopy Technology
4. Spectros Presents at the Pediatric Academic Societies (PAS) National Conference 2010
5. Spectros Corp. Enters Into Optical Biotechnology Patent Sale Agreement With Philips Electronics N.V.
6. Bioimpedance Spectroscopy is More Accurate and Reliable Than Other Methods of Subclinical Assessment of Lymphedema in Breast Cancer Patients, According to Paper Published in Journal of Clinical Oncology
7. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
8. Luminex Corporation Reports Fourth Quarter and Full Year 2010 Results
9. Unilife Corporation to Announce Financial Results for Fiscal 2011 Second Quarter on Monday, February 14, 2011
10. China Medicine Corporation Receives Manufacturing License for rADTZ
11. Endo Pharmaceuticals and Orion Corporation Begin Novel R&D Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Oct. 2, 2017 Halo Labs announces the European launch ... called the HORIZON at MIBio 2017 in Cambridge, U.K ... visible particulate matter in biopharmaceutical samples with unprecedented speed and sensitivity ... novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... The American Board of Family Medicine's (ABFM) Board of Directors has selected ... Dr. James C. Puffer upon his retirement. Dr. Newton will serve in the position ... the end of 2018. Upon assuming the role of President and CEO on January ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a ... utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the ... a CBD form that can be easily incorporated into liquid products, while reducing costs ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Lori R. Somekh, ... member of ElderCounsel, a national organization of elder law and special needs planning attorneys. ... and rules. It also provides a forum to network with elder law attorneys nationwide,” ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
Breaking Medicine News(10 mins):